2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Monday, December 14, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Access, Representation, Population Health, Technology and Procedures, Molecular Testing, Pathology, Treatment Considerations, Supportive Care, Therapy Sequence, Biological Therapies, Transfusion, Immunotherapy, Non-Biological Therapies, Anticoagulant Drugs, Women’s Health, Adverse Events, Clinical Practice (Health Services and Quality), Clinical Guidelines, Quality of Care, Systems-Based Hematology, Value, Diseases, Bleeding and Clotting, Bleeding Disorders, Hemophilia, Thromboembolism, Thrombotic Disorders, Bone Marrow Failure Syndromes, Acquired Marrow Failure Syndromes , Inherited Marrow Failure Syndromes, Aplastic Anemia, Genetic Disorders, Immunology, Autoimmune Hemolytic Anemia, Neutropenia, Infectious Diseases, Viral, Bacterial, Fungal, Myeloid Malignancies, Chronic Myeloid Malignancies, Metabolic Disorders, Iron Deficiency, Research, MPN, Clinical Research, Epidemiology, Health Outcomes Research, Health Disparities Research, Patient-Reported Outcomes, Real-World Evidence, Study Population, Human, Adult, Pediatric, Pregnant, Young Adult
PAPER

6222 Anticoagulation after thrombosis in patients with PNH receiving complement inhibitors: What are we actually doing?

Tinatin Muradashvili, MD, Mohamad Ali Tfaily, MD MS2, Morgan McLemore, MD3
1 Emory University, Atlanta, Georgia, United States
2 Emory University, Atlanta, Georgia, United States
3 Emory University, Atlanta, Georgia, United States

Thrombosis remains the leading cause of death in paroxysmal nocturnal hemoglobinuria (PNH). Although complement inhibition reduces thrombotic risk by more than 80%, it does not eliminate it, and patients who develop thrombosis still require anticoagulation. No guidelines favor one anticoagulant over another. Evidence supporting direct oral anticoagulants (DOACs) in PNH is limited to small retrospective series, with no direct comparisons with warfarin. Despite this limited evidence, warfarin remains commonly used based largely on data from the pre-eculizumab era, and real-world practice remains heterogeneous. We therefore characterized trends in anticoagulant selection after thrombosis in complement inhibitor–treated PNH.

We queried Epic Cosmos, a federated, deidentified electronic health record database spanning 2,198 hospitals and more than 310 million patients, from October 2015 through June 2026. We identified adults aged ≥18 years with PNH (ICD-10-CM D59.5) who were receiving a complement inhibitor - eculizumab, ravulizumab, crovalimab, pegcetacoplan, or iptacopan - and sustained a venous or arterial thrombotic event no earlier than 30 days from PNH diagnosis. Patients with antiphospholipid syndrome were excluded. Anticoagulant treatment recorded within 30 days of thrombosis was classified as a DOAC (apixaban or rivaroxaban), warfarin or low-molecular-weight heparin (LMWH), or none. Anticoagulant selection was assessed by calendar year of thrombosis. Recurrent thrombosis after anticoagulant initiation could not be ascertained because diagnosis codes could not distinguish a new event from ongoing documentation of the index thrombus accurately; analyses were therefore limited to describing anticoagulant selection.

Among 622 patients who developed thrombosis while receiving complement inhibitor therapy, the median age was 54 years; 58.9% were female and 41.1% were male, with fewer than 10 patients of unknown. Overall, 245 (39.4%) received a DOAC, 248 (39.9%) received warfarin/LMWH, and 129 (20.7%) had no recorded anticoagulant.

DOAC use increased from approximately 14% in 2017 to 46% in 2025, surpassing warfarin/LMWH in 2021 and remaining higher thereafter. Warfarin/LMWH use declined from a peak of approximately 45% to 28% but remained above 25% throughout the study period. The annual proportion of patients without recorded anticoagulation increased to 52% over the last year.

Anticoagulant selection after thrombosis in complement inhibitor–treated PNH was nearly evenly divided between DOACs and warfarin/LMWH, and one in six patients had no anticoagulant recorded. The absence of recorded anticoagulation may reflect a perception that complement inhibition alone provides sufficient thromboprophylaxis, although incomplete capture of inpatient or out-of-system treatment cannot be excluded. DOAC use increased steadily and now predominates, yet more than one-quarter of patients continue to receive warfarin/LMWH. Whether this reflects clinical inertia or appropriate caution cannot be determined from these data. This clinical equipoise supports further comparative investigation. 

Tinatin Muradashvili, MD: No relevant conflicts of interest to declare.